Developer docs
API playgroundTry for free, no card

Search company profiles

Three Lakes 12-20

Full company profile

uuid00ygta2

Namestring
Three Lakes 12-20
Legal namestring
Three Lakes 12-20 Pulmonary Fibrosis Research Foundation
Company typeenum
Private
Founded yearint
2025
Descriptiontext

Three Lakes 12-20 (TL 12-20) is a public 501(c)(3) research foundation operating within New Venture Fund, established in 2025 to accelerate the development of effective therapies and translational resources for pulmonary fibrosis (PF) and interstitial lung disease (ILD). It is the successor to Three Lakes Foundation, a private foundation originally funded by a family affected by idiopathic pulmonary fibrosis, and inherits a research portfolio that has channeled more than $20M toward PF initiatives since 2020. The foundation serves three primary beneficiary groups: PF and ILD patients (an estimated 100,000+ US patients with median 3-5 year survival post-diagnosis), translational researchers facing funding gaps in the "valley of death" between discovery and clinical development, and clinicians needing better diagnostic and educational tools.

The foundation operates a portfolio of research programs rather than commercial products. Core translational assets include PF-COLLECT (a pharmaceutical-foundation consortium validating cryopreserved human precision cut lung slices), the IPF Cell Atlas (open-source single-cell RNA sequencing resource co-developed with Yale and Baylor), TLC4PF (AI and single-cell profiling consortium with Yale and Pittsburgh including the Unagi perturbation simulator), PROLIFIC (blood-based biomarker assay consortium with pharma), and the B4PF1.0/B4PF2.0 early-detection programs at Vanderbilt. Diagnostic and educational tools include Mayo Clinic's AI-based EHR screening for IPF and the TED-IPF CT prediction tool, the CHEST Bridging Specialties Toolkit, and the Ask the Expert series. The foundation also supports multiple clinical trials spanning telomere biology (Telomere Trial), repurposed therapeutics (Metformin, Zinc/Nicotinamide Riboside, EGCG), genomic-stratified care (PRECISIONS), and pragmatic antimicrobial therapy (Clean-UP IPF with Duke). Strategic academic and clinical partners include Mayo Clinic, Yale, Vanderbilt, Cedars-Sinai, Baylor, University of Pittsburgh, Weill Cornell, Duke Clinical Research Institute, the Pulmonary Fibrosis Foundation, NHLBI, and Lung Foundation Australia.

TL 12-20's revenue model is philanthropic: it accepts donations via credit card, ACH, wire, check, and stock, with administrative costs fully covered by an anonymous donor through 2026 so that 100% of new contributions flow directly to research. Distribution of "outputs" occurs through direct research grants to academic investigators, collaborative consortia with pharmaceutical companies, and educational content deployed via conferences (ATS, ICLAF, Team Telomere, FusionLung26), website/blog, email newsletter, and LinkedIn. Patient delegate stories and the Make Connor Run fundraising campaign drive community engagement and donor cultivation.

Short descriptiontext

Three Lakes 12-20 is a public 501(c)(3) research foundation that funds and coordinates translational research, clinical trials, and AI-driven diagnostic tools for pulmonary fibrosis and interstitial lung disease, serving patients, academic researchers, and clinicians.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWashington, United States
HQ citystring
Washington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pulmonary fibrosis research, interstitial lung disease, medical research foundation, clinical trial funding, translational medicine
Industry4 codes
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJALAO
International & Global Public Health Aid Administration (Government Donors)
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration
NAICS code5 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Grantmaking and Giving Services81321
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Medical Research Foundation
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Philanthropic Contributions
TypeAffiliate Referral
Description

As a 501(c)(3) public charity operating within New Venture Fund, Three Lakes 12-20 raises funds from donors to support pulmonary fibrosis research. Administrative costs are covered through 2026 by an anonymous donor, allowing 100% of donations to be directed to research projects.

threelakes1220.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1PF-COLLECT
Description

Pulmonary Fibrosis Consortium for Living Lung Excised Tissue - A consortium consisting of Pharmaceutical and Foundation Members who collaborate to validate cryopreservation and develop human-based tissue resources and assays to accelerate the development of therapies for ILD and PF.

threelakes1220.org
Core offering1 text field

Three Lakes 12-20 is a public research foundation that funds, coordinates, and accelerates pulmonary fibrosis (PF) and interstitial lung disease (ILD) research. Its core offerings include the PF-COLLECT Consortium for human tissue resources, the IPF Cell Atlas open-source single-cell RNA sequencing resource, the TLC4PF and PROLIFIC AI/single-cell consortia, the B4PF1.0/B4PF2.0 early disease detection programs, multiple funded clinical trials, the CHEST Bridging Specialties diagnostic tool, and the Ask the Expert educational series. The foundation operates within New Venture Fund as a 501(c)(3) public charity and channels 100% of donations to research through 2026.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over $20M administered toward PF research initiatives since 2020
+3 more records
Product overview1 text field

Three Lakes 12-20 is a public research foundation (operating within the New Venture Fund) focused on accelerating development of effective therapies and translational resources for pulmonary fibrosis (PF) and interstitial lung disease (ILD). Rather than offering commercial products, the foundation operates a portfolio of research initiatives and programs: the PF-COLLECT Consortium for developing human tissue resources; the IPF Cell Atlas, PROLIFIC Consortium, and TLC4PF research initiatives using AI and single-cell profiling; B4PF1.0/B4PF2.0 for early disease research; and the Mayo Clinic diagnostic tools including AI-based screening. The foundation also funds multiple clinical trials (Telomere Trial, Zinc/NR, Metformin, EGCG, PRECISIONS, Clean-UP IPF), an Ask the Expert educational series, the CHEST Bridging Specialties diagnostic tool, and the Make Connor Run fundraising program. Administrative costs are covered through 2026 via anonymous donor, enabling 100% of donations to fund critical research projects.

Product and service13 records
1PF-COLLECT Consortium
Categoryresearch initiative
Description

Pulmonary Fibrosis Consortium for Living Lung Excised Tissue (PF-COLLECT). A consortium of pharmaceutical and foundation members that collaborate to validate cryopreservation and develop human-based tissue resources and assays to accelerate development of therapies for ILD and PF. Designed for pharmaceutical researchers and academic investigators needing access to validated human precision cut lung slices (hPCLS).

2IPF Cell Atlas
Categoryresearch tool
Description

Collaborative open-source resource enabling researchers to explore single-cell RNA sequencing datasets from IPF tissue. Contains data from hundreds of thousands of cells from healthy and diseased lungs and enables identification of cell populations driving disease including aberrant basaloid cells, profibrotic macrophages, and expanded vascular endothelial cells.

3PROLIFIC Consortium
Categoryresearch initiative
Description

Consortium developing well-qualified assays to measure selected blood-based protein biomarkers linked to IPF. Involves leading pharmaceutical companies and foundations focused on PF/ILD biomarker validation.

4TLC4PF (Three Lakes Consortium for Pulmonary Fibrosis)
Categoryresearch initiative
Description

Consortium using AI and cutting-edge single-cell profiling technologies to identify potential treatments for PF and validate efficacy with human tissue-based models. Includes the Pulmonary Fibrosis Connectome workgroup at Yale and the PF Translation workgroup at University of Pittsburgh; the McGill team created the Unagi webserver for exploring cellular dynamics and simulating perturbations.

5B4PF1.0 and B4PF2.0 (Before the PF)
Categoryresearch initiative
Description

Research programs studying subclinical or early disease in asymptomatic relatives of PF patients to understand natural progression and identify biomarkers and drug targets. B4PF1.0 uses single-cell sequencing and spatial transcriptomics on lung biopsy samples; B4PF2.0 analyzes HRCT scans using radiomic signatures for disease risk and progression prediction.

6Ask the Expert Series
Categoryeducational program
Description

Forum providing access to industry professionals working towards treatment and future of pulmonary fibrosis. Monthly expert Q&A sessions with leading researchers and clinicians for patients, caregivers, and clinicians.

7CHEST Bridging Specialties Tool
Categoryeducational tool
Description

Multiphase educational tool designed to reduce diagnostic delays for patients with Interstitial Lung Diseases including pulmonary fibrosis. Contains ILD-specific patient questionnaire, e-learning module, and decision-making tool developed for clinicians and pulmonologists.

8Telomere Trial
Categoryclinical trial
Description

Phase I clinical trial assessing safety and biological effects of deoxycytidine plus thymidine to lengthen telomeres in PF patients, addressing telomere shortening linked to worse prognosis. Targets PF patients with short telomere signatures.

9Zinc and Nicotinamide Riboside Trial
Categoryclinical trial
Description

Decentralized, double-blind randomized controlled trial testing combination of zinc and nicotinamide riboside in patients with IPF, targeting mitochondrial function, DNA repair, and energy metabolism via NAD+. Led by Dr. Tanzira Zaman at Cedars-Sinai.

10Metformin Study
Categoryclinical trial
Description

Clinical trial validating whether patients with pulmonary fibrosis benefit from treatment with metformin, building on findings that patients with both PF and type 2 diabetes treated with metformin had reduced mortality and hospitalizations.

11PRECISIONS Trial
Categoryclinical trial
Description

First pulmonary fibrosis trial using a genomic-driven approach to identify patients most likely to respond to treatment with N-Acetylcysteine (NAC), using blood transcriptomics, proteomics, and genomics.

12Clean-UP IPF
Categoryclinical trial
Description

First pragmatic trial in IPF studying whether antimicrobial therapy improves hospitalization or decreases death, evaluating effectiveness in real-life settings. Coordinated with Duke Clinical Research Institute and supported by NHLBI.

13Make Connor Run
Categoryfundraising program
Description

Annual fundraising campaign where Connor Tully runs 1 mile for every $50 raised in June on behalf of his father, Tom Tully, a pulmonary fibrosis patient and lung transplant recipient. Funds support early detection and prevention research.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership17 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-08-06
Description

Global collaboration between Three Lakes Foundation, Lung Foundation Australia, and Australian Centre of Research Excellence for Pulmonary Fibrosis. Focused on leveraging expertise, resources, and knowledge to accelerate diagnosis, treatment, and delivery of therapies. CRE-PF supports research, educates public, and trains researchers in PF.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-10
Description

Three Lakes 12-20 and PFF share common goals to improve lives of PF patients. Founders have provided support for PFF patient registry, driving awareness, and research into PF causes. Collaborated with NHLBI and PFF on 2022 stakeholder summit to identify scientific gaps and research opportunities. Results published in Pulmonary Fibrosis Stakeholder Summit workshop report.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Grant from Three Lakes Foundation to Wescoe Foundation to support their work understanding needs and interests of PF patients and families. Aligned vision to unite the PF community and accelerate research and therapies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

PF Warriors serves global PF/ILD patient community with tools, resources, peer-to-peer programs, and webinars. Three Lakes 12-20 is aligned with their mission to help families affected by PF.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Mayo Clinic collaboration mapped diagnostic journey for PF, defined impact of existing therapies, and developed AI diagnostic tools. Led by Dr. Andrew Limper, developed electronic health record screening tools and identified metformin therapy potential.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Zinc and Nicotinamide Riboside trial led by Dr. Tanzira Zaman at Cedars-Sinai. Original work from Dr. Paul Noble on ZIP8/SIRT1 axis regulating alveolar progenitor cell renewal. Trial tests decentralized RCT approach for IPF treatment.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TLC4PF consortium collaboration with Yale led by Dr. Naftali Kaminski. Pulmonary Fibrosis Connectome workgroup uses AI and single-cell profiling to identify treatments. Led development of IPF Cell Atlas.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TLC4PF consortium collaboration with University of Pittsburgh. PF Translation workgroup led by Dr. Melanie Koenigshoff focuses on advancing treatments through translational research and organoid models.

9Vanderbilt University Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

B4PF1.0 and B4PF2.0 projects led by Dr. Jonathan Kropski studying subclinical PF in first-degree relatives. Uses single-cell sequencing, spatial transcriptomics, and radiomic signatures for early detection.

threelakes1220.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

IPF Cell Atlas development led by Dr. Ivan O. Rosas at Baylor. Collaborative open-source resource with Yale University containing hundreds of thousands of cells from healthy and diseased lungs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Three Lakes 12-20 is a member of PROLIFIC Consortium developing assays to measure blood-based protein biomarkers linked to IPF. Consortium includes leading pharmaceutical companies and foundations.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated with NHLBI and PFF on 2022 stakeholder summit. Supported Clean-UP IPF pragmatic trial. Joint initiative to identify scientific gaps and research opportunities in PF.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Foundation attends ATS International Conference (Orlando, FL, May 2026) - world's most important gathering for pulmonary, critical care, and sleep professionals.

14International Colloquium on Lung and Airway Fibrosis (ICLAF)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Foundation attends ICLAF (Sydney, Australia, October 2026) - biennial meeting convening to discuss cutting-edge advancements in pathogenesis, management and therapies for pulmonary fibrosis.

threelakes1220.org
15Team Telomere
Strategic tierMinorTypeGTM or Marketing Partner
Description

Foundation attends Team Telomere Scientific Summit (Missoula, Montana, July 2026) - dynamic convening of clinicians, researchers, advocates, and community leaders exploring Telomere Biology Disorders.

threelakes1220.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Initial funding provided by Three Lakes Foundation for CHEST Bridging Specialties Tool - multiphase educational initiative to reduce diagnostic delays for ILD patients.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clean-UP IPF pragmatic trial collaboration with DCRI as coordinating center for NHLBI-sponsored study on antimicrobial therapy effectiveness.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A disease-specific lung research foundation that pioneered the venture philanthropy model for drug development. Highly comparable in structure and mission (single-disease lung foundation funding R&D) though at vastly greater scale.

TypeBroad incumbent
Description

The largest US lung health nonprofit, with broad research, advocacy, and education programs including some PF funding. Comparable as an incumbent in lung disease research funding though with a much broader mandate.

TypeDirect peer
Description

The largest US nonprofit dedicated to pulmonary fibrosis, operating a patient registry, support programs, and research funding. TL 12-20 and PFF share core goals and have collaborated on the 2022 NHLBI stakeholder summit; PFF is the most direct disease-focused peer.

TypeDirect peer
Description

A global PF/ILD patient community organization offering peer-to-peer programs, resources, and webinars. Direct peer in serving the same patient community with aligned mission.

TypeDirect peer
Description

A smaller PF-focused foundation that has received grants from TL 12-20. Directly comparable as a patient-support and PF research nonprofit serving the same community.

6Team Telomere
TypeDirect peer
Description

A small nonprofit focused on Telomere Biology Disorders, a related disease area that intersects with PF. TL 12-20 attends the Team Telomere Scientific Summit, signaling collaboration; comparable as a small rare-disease foundation model.

TypeEmerging player
Description

An emerging biotech developing anti-fibrotic therapies, founded by Dr. Paul Yaworsky who sits on TL 12-20's advisory board. Comparable as a translational PF drug development effort that the foundation's research programs aim to feed.

TypeOthers
Description

The US government's primary funder of PF research, and a direct collaborator on the 2022 stakeholder summit and Clean-UP IPF trial. Comparable as a co-funder of the PF research ecosystem though not a competitor for donations.

TypeEmerging player
Description

Clinical-stage biotech developing integrin-based therapies for IPF and other fibrotic diseases. Comparable as a PF drug developer whose translational work overlaps with TL 12-20's mission.

TypeDirect peer
Description

Australia's primary lung disease foundation and the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF). Direct strategic partner of TL 12-20 with mutual collaboration on global PF research, training, and education initiatives.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability11 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Three Lakes 12-20

Medical Research Foundationthreelakes1220.org

Three Lakes 12-20 is a public 501(c)(3) research foundation that funds and coordinates translational research, clinical trials, and AI-driven diagnostic tools for pulmonary fibrosis and interstitial lung disease, serving patients, academic researchers, and clinicians.

What Three Lakes 12-20 does

Three Lakes 12-20 (TL 12-20) is a public 501(c)(3) research foundation operating within New Venture Fund, established in 2025 to accelerate the development of effective therapies and translational resources for pulmonary fibrosis (PF) and interstitial lung disease (ILD). It is the successor to Three Lakes Foundation, a private foundation originally funded by a family affected by idiopathic pulmonary fibrosis, and inherits a research portfolio that has channeled more than $20M toward PF initiatives since 2020. The foundation serves three primary beneficiary groups: PF and ILD patients (an estimated 100,000+ US patients with median 3-5 year survival post-diagnosis), translational researchers facing funding gaps in the "valley of death" between discovery and clinical development, and clinicians needing better diagnostic and educational tools.

The foundation operates a portfolio of research programs rather than commercial products. Core translational assets include PF-COLLECT (a pharmaceutical-foundation consortium validating cryopreserved human precision cut lung slices), the IPF Cell Atlas (open-source single-cell RNA sequencing resource co-developed with Yale and Baylor), TLC4PF (AI and single-cell profiling consortium with Yale and Pittsburgh including the Unagi perturbation simulator), PROLIFIC (blood-based biomarker assay consortium with pharma), and the B4PF1.0/B4PF2.0 early-detection programs at Vanderbilt. Diagnostic and educational tools include Mayo Clinic's AI-based EHR screening for IPF and the TED-IPF CT prediction tool, the CHEST Bridging Specialties Toolkit, and the Ask the Expert series. The foundation also supports multiple clinical trials spanning telomere biology (Telomere Trial), repurposed therapeutics (Metformin, Zinc/Nicotinamide Riboside, EGCG), genomic-stratified care (PRECISIONS), and pragmatic antimicrobial therapy (Clean-UP IPF with Duke). Strategic academic and clinical partners include Mayo Clinic, Yale, Vanderbilt, Cedars-Sinai, Baylor, University of Pittsburgh, Weill Cornell, Duke Clinical Research Institute, the Pulmonary Fibrosis Foundation, NHLBI, and Lung Foundation Australia.

TL 12-20's revenue model is philanthropic: it accepts donations via credit card, ACH, wire, check, and stock, with administrative costs fully covered by an anonymous donor through 2026 so that 100% of new contributions flow directly to research. Distribution of "outputs" occurs through direct research grants to academic investigators, collaborative consortia with pharmaceutical companies, and educational content deployed via conferences (ATS, ICLAF, Team Telomere, FusionLung26), website/blog, email newsletter, and LinkedIn. Patient delegate stories and the Make Connor Run fundraising campaign drive community engagement and donor cultivation.

Three Lakes 12-20 firmographics

Firmographics
Name
Three Lakes 12-20
Legal name
Three Lakes 12-20 Pulmonary Fibrosis Research Foundation
Website
https://threelakes1220.org
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
Three Lakes 12-20 is a public 501(c)(3) research foundation that funds and coordinates translational research, clinical trials, and AI-driven diagnostic tools for pulmonary fibrosis and interstitial lung disease, serving patients, academic researchers, and clinicians.
Ownership category
akta.pro rank

Three Lakes 12-20 industry classification

Industry
Product category
Medical Research Foundation
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Grantmaking and Giving Services (81321)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJALAO
International & Global Public Health Aid Administration (Government Donors)
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration

Keywords

  • Pulmonary fibrosis research
  • Interstitial lung disease
  • Medical research foundation
  • Clinical trial funding
  • Translational medicine

Where Three Lakes 12-20 is headquartered

Location

Headquarters

HQ city
Washington
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Three Lakes 12-20 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Donations and Philanthropic Contributions: As a 501(c)(3) public charity operating within New Venture Fund, Three Lakes 12-20 raises funds from donors to support pulmonary fibrosis research. Administrative costs are covered through 2026 by an anonymous donor, allowing 100% of donations to be directed to research projects.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Three Lakes 12-20 product offering

Product offering

Core offering

Three Lakes 12-20 is a public research foundation that funds, coordinates, and accelerates pulmonary fibrosis (PF) and interstitial lung disease (ILD) research. Its core offerings include the PF-COLLECT Consortium for human tissue resources, the IPF Cell Atlas open-source single-cell RNA sequencing resource, the TLC4PF and PROLIFIC AI/single-cell consortia, the B4PF1.0/B4PF2.0 early disease detection programs, multiple funded clinical trials, the CHEST Bridging Specialties diagnostic tool, and the Ask the Expert educational series. The foundation operates within New Venture Fund as a 501(c)(3) public charity and channels 100% of donations to research through 2026.

Product overview

Three Lakes 12-20 is a public research foundation (operating within the New Venture Fund) focused on accelerating development of effective therapies and translational resources for pulmonary fibrosis (PF) and interstitial lung disease (ILD). Rather than offering commercial products, the foundation operates a portfolio of research initiatives and programs: the PF-COLLECT Consortium for developing human tissue resources; the IPF Cell Atlas, PROLIFIC Consortium, and TLC4PF research initiatives using AI and single-cell profiling; B4PF1.0/B4PF2.0 for early disease research; and the Mayo Clinic diagnostic tools including AI-based screening. The foundation also funds multiple clinical trials (Telomere Trial, Zinc/NR, Metformin, EGCG, PRECISIONS, Clean-UP IPF), an Ask the Expert educational series, the CHEST Bridging Specialties diagnostic tool, and the Make Connor Run fundraising program. Administrative costs are covered through 2026 via anonymous donor, enabling 100% of donations to fund critical research projects.

Differentiator

Problem solved

Functional benefit

Brands

  • PF-COLLECT: Pulmonary Fibrosis Consortium for Living Lung Excised Tissue - A consortium consisting of Pharmaceutical and Foundation Members who collaborate to validate cryopreservation and develop human-based tissue resources and assays to accelerate the development of therapies for ILD and PF.

Products and services

  • PF-COLLECT Consortium Pulmonary Fibrosis Consortium for Living Lung Excised Tissue (PF-COLLECT). A consortium of pharmaceutical and foundation members that collaborate to validate cryopreservation and develop human-based tissue resources and assays to accelerate development of therapies for ILD and PF. Designed for pharmaceutical researchers and academic investigators needing access to validated human precision cut lung slices (hPCLS).
  • IPF Cell Atlas Collaborative open-source resource enabling researchers to explore single-cell RNA sequencing datasets from IPF tissue. Contains data from hundreds of thousands of cells from healthy and diseased lungs and enables identification of cell populations driving disease including aberrant basaloid cells, profibrotic macrophages, and expanded vascular endothelial cells.
  • PROLIFIC Consortium Consortium developing well-qualified assays to measure selected blood-based protein biomarkers linked to IPF. Involves leading pharmaceutical companies and foundations focused on PF/ILD biomarker validation.
  • TLC4PF (Three Lakes Consortium for Pulmonary Fibrosis) Consortium using AI and cutting-edge single-cell profiling technologies to identify potential treatments for PF and validate efficacy with human tissue-based models. Includes the Pulmonary Fibrosis Connectome workgroup at Yale and the PF Translation workgroup at University of Pittsburgh; the McGill team created the Unagi webserver for exploring cellular dynamics and simulating perturbations.
  • B4PF1.0 and B4PF2.0 (Before the PF) Research programs studying subclinical or early disease in asymptomatic relatives of PF patients to understand natural progression and identify biomarkers and drug targets. B4PF1.0 uses single-cell sequencing and spatial transcriptomics on lung biopsy samples; B4PF2.0 analyzes HRCT scans using radiomic signatures for disease risk and progression prediction.
  • Ask the Expert Series Forum providing access to industry professionals working towards treatment and future of pulmonary fibrosis. Monthly expert Q&A sessions with leading researchers and clinicians for patients, caregivers, and clinicians.
  • CHEST Bridging Specialties Tool Multiphase educational tool designed to reduce diagnostic delays for patients with Interstitial Lung Diseases including pulmonary fibrosis. Contains ILD-specific patient questionnaire, e-learning module, and decision-making tool developed for clinicians and pulmonologists.
  • Telomere Trial Phase I clinical trial assessing safety and biological effects of deoxycytidine plus thymidine to lengthen telomeres in PF patients, addressing telomere shortening linked to worse prognosis. Targets PF patients with short telomere signatures.
  • Zinc and Nicotinamide Riboside Trial Decentralized, double-blind randomized controlled trial testing combination of zinc and nicotinamide riboside in patients with IPF, targeting mitochondrial function, DNA repair, and energy metabolism via NAD+. Led by Dr. Tanzira Zaman at Cedars-Sinai.
  • Metformin Study Clinical trial validating whether patients with pulmonary fibrosis benefit from treatment with metformin, building on findings that patients with both PF and type 2 diabetes treated with metformin had reduced mortality and hospitalizations.
  • PRECISIONS Trial First pulmonary fibrosis trial using a genomic-driven approach to identify patients most likely to respond to treatment with N-Acetylcysteine (NAC), using blood transcriptomics, proteomics, and genomics.
  • Clean-UP IPF First pragmatic trial in IPF studying whether antimicrobial therapy improves hospitalization or decreases death, evaluating effectiveness in real-life settings. Coordinated with Duke Clinical Research Institute and supported by NHLBI.
  • Make Connor Run Annual fundraising campaign where Connor Tully runs 1 mile for every $50 raised in June on behalf of his father, Tom Tully, a pulmonary fibrosis patient and lung transplant recipient. Funds support early detection and prevention research.

Quantifiable outcome

  • Over $20M administered toward PF research initiatives since 2020
  • +3 more outcomes

Companies that use Three Lakes 12-20

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Three Lakes 12-20 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature5 records

Three Lakes 12-20 partnerships and signals

Strategic signal

Partnerships

17 partnerships are on record, tiered core and minor.

  • Lung Foundation Australia / CRE-PFcoreStrategic or Co-development Partner · 6 August 2021Global collaboration between Three Lakes Foundation, Lung Foundation Australia, and Australian Centre of Research Excellence for Pulmonary Fibrosis. Focused on leveraging expertise, resources, and knowledge to accelerate diagnosis, treatment, and delivery of therapies. CRE-PF supports research, educates public, and trains researchers in PF.
  • Pulmonary Fibrosis Foundation (PFF)coreStrategic or Co-development Partner · 10 March 2021Three Lakes 12-20 and PFF share common goals to improve lives of PF patients. Founders have provided support for PFF patient registry, driving awareness, and research into PF causes. Collaborated with NHLBI and PFF on 2022 stakeholder summit to identify scientific gaps and research opportunities. Results published in Pulmonary Fibrosis Stakeholder Summit workshop report.
  • Wescoe FoundationminorStrategic or Co-development PartnerGrant from Three Lakes Foundation to Wescoe Foundation to support their work understanding needs and interests of PF patients and families. Aligned vision to unite the PF community and accelerate research and therapies.
  • PF WarriorsminorStrategic or Co-development PartnerPF Warriors serves global PF/ILD patient community with tools, resources, peer-to-peer programs, and webinars. Three Lakes 12-20 is aligned with their mission to help families affected by PF.
  • Mayo CliniccoreStrategic or Co-development PartnerMayo Clinic collaboration mapped diagnostic journey for PF, defined impact of existing therapies, and developed AI diagnostic tools. Led by Dr. Andrew Limper, developed electronic health record screening tools and identified metformin therapy potential.
  • Cedars-SinaicoreStrategic or Co-development PartnerZinc and Nicotinamide Riboside trial led by Dr. Tanzira Zaman at Cedars-Sinai. Original work from Dr. Paul Noble on ZIP8/SIRT1 axis regulating alveolar progenitor cell renewal. Trial tests decentralized RCT approach for IPF treatment.
  • Yale University School of MedicinecoreStrategic or Co-development PartnerTLC4PF consortium collaboration with Yale led by Dr. Naftali Kaminski. Pulmonary Fibrosis Connectome workgroup uses AI and single-cell profiling to identify treatments. Led development of IPF Cell Atlas.
  • University of Pittsburgh School of MedicinecoreStrategic or Co-development PartnerTLC4PF consortium collaboration with University of Pittsburgh. PF Translation workgroup led by Dr. Melanie Koenigshoff focuses on advancing treatments through translational research and organoid models.
  • Vanderbilt University Medical CentercoreStrategic or Co-development PartnerB4PF1.0 and B4PF2.0 projects led by Dr. Jonathan Kropski studying subclinical PF in first-degree relatives. Uses single-cell sequencing, spatial transcriptomics, and radiomic signatures for early detection.
  • Baylor College of MedicinecoreStrategic or Co-development PartnerIPF Cell Atlas development led by Dr. Ivan O. Rosas at Baylor. Collaborative open-source resource with Yale University containing hundreds of thousands of cells from healthy and diseased lungs.
  • PROLIFIC ConsortiumcoreStrategic or Co-development PartnerThree Lakes 12-20 is a member of PROLIFIC Consortium developing assays to measure blood-based protein biomarkers linked to IPF. Consortium includes leading pharmaceutical companies and foundations.
  • National Heart, Lung, and Blood Institute (NHLBI)coreStrategic or Co-development PartnerCollaborated with NHLBI and PFF on 2022 stakeholder summit. Supported Clean-UP IPF pragmatic trial. Joint initiative to identify scientific gaps and research opportunities in PF.
  • American Thoracic Society (ATS)minorGTM or Marketing PartnerFoundation attends ATS International Conference (Orlando, FL, May 2026) - world's most important gathering for pulmonary, critical care, and sleep professionals.
  • International Colloquium on Lung and Airway Fibrosis (ICLAF)minorGTM or Marketing PartnerFoundation attends ICLAF (Sydney, Australia, October 2026) - biennial meeting convening to discuss cutting-edge advancements in pathogenesis, management and therapies for pulmonary fibrosis.
  • Team TelomereminorGTM or Marketing PartnerFoundation attends Team Telomere Scientific Summit (Missoula, Montana, July 2026) - dynamic convening of clinicians, researchers, advocates, and community leaders exploring Telomere Biology Disorders.
  • American College of Chest Physicians (CHEST)coreStrategic or Co-development PartnerInitial funding provided by Three Lakes Foundation for CHEST Bridging Specialties Tool - multiphase educational initiative to reduce diagnostic delays for ILD patients.
  • Duke Clinical Research InstituteminorStrategic or Co-development PartnerClean-UP IPF pragmatic trial collaboration with DCRI as coordinating center for NHLBI-sponsored study on antimicrobial therapy effectiveness.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Three Lakes 12-20 competitors and assessment

Company assessment

Direct peers

  • Cystic Fibrosis Foundation: A disease-specific lung research foundation that pioneered the venture philanthropy model for drug development. Highly comparable in structure and mission (single-disease lung foundation funding R&D) though at vastly greater scale.
  • Pulmonary Fibrosis Foundation: The largest US nonprofit dedicated to pulmonary fibrosis, operating a patient registry, support programs, and research funding. TL 12-20 and PFF share core goals and have collaborated on the 2022 NHLBI stakeholder summit; PFF is the most direct disease-focused peer.
  • PF Warriors: A global PF/ILD patient community organization offering peer-to-peer programs, resources, and webinars. Direct peer in serving the same patient community with aligned mission.
  • Wescoe Foundation for Pulmonary Fibrosis: A smaller PF-focused foundation that has received grants from TL 12-20. Directly comparable as a patient-support and PF research nonprofit serving the same community.
  • Team Telomere: A small nonprofit focused on Telomere Biology Disorders, a related disease area that intersects with PF. TL 12-20 attends the Team Telomere Scientific Summit, signaling collaboration; comparable as a small rare-disease foundation model.
  • Lung Foundation Australia / CRE-PF: Australia's primary lung disease foundation and the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF). Direct strategic partner of TL 12-20 with mutual collaboration on global PF research, training, and education initiatives.

Broad incumbents

  • American Lung Association: The largest US lung health nonprofit, with broad research, advocacy, and education programs including some PF funding. Comparable as an incumbent in lung disease research funding though with a much broader mandate.

Emerging players

  • Mediar Therapeutics: An emerging biotech developing anti-fibrotic therapies, founded by Dr. Paul Yaworsky who sits on TL 12-20's advisory board. Comparable as a translational PF drug development effort that the foundation's research programs aim to feed.
  • Pliant Therapeutics: Clinical-stage biotech developing integrin-based therapies for IPF and other fibrotic diseases. Comparable as a PF drug developer whose translational work overlaps with TL 12-20's mission.

Others

  • National Heart, Lung, and Blood Institute (NHLBI): The US government's primary funder of PF research, and a direct collaborator on the 2022 stakeholder summit and Clean-UP IPF trial. Comparable as a co-funder of the PF research ecosystem though not a competitor for donations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Three Lakes 12-20 social profiles

Digital presence

Three Lakes 12-20 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Three Lakes 12-20 leadership team

Management profile

Number of profiles

Profiles4 records

Three Lakes 12-20 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Three Lakes 12-20 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Three Lakes 12-20

What does Three Lakes 12-20 do?

Three Lakes 12-20 is a public research foundation that funds, coordinates, and accelerates pulmonary fibrosis (PF) and interstitial lung disease (ILD) research. Its core offerings include the PF-COLLECT Consortium for human tissue resources, the IPF Cell Atlas open-source single-cell RNA sequencing resource, the TLC4PF and PROLIFIC AI/single-cell consortia, the B4PF1.0/B4PF2.0 early disease detection programs, multiple funded clinical trials, the CHEST Bridging Specialties diagnostic tool, and the Ask the Expert educational series. The foundation operates within New Venture Fund as a 501(c)(3) public charity and channels 100% of donations to research through 2026.

Is Three Lakes 12-20 a public or private company?

Three Lakes 12-20 is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Three Lakes 12-20 founded?

Three Lakes 12-20 was founded in 2025. It employs 1 to 10 people.

Where is Three Lakes 12-20 based?

Three Lakes 12-20 is headquartered in Washington, United States, in the North America region.

How does Three Lakes 12-20 make money?

One revenue line is on record: donations and Philanthropic Contributions.

Who are Three Lakes 12-20's main competitors?

Direct peers on record are Cystic Fibrosis Foundation, Pulmonary Fibrosis Foundation, PF Warriors, Wescoe Foundation for Pulmonary Fibrosis, Team Telomere and Lung Foundation Australia / CRE-PF. American Lung Association is listed as a broad incumbent. Emerging players are Mediar Therapeutics and Pliant Therapeutics. National Heart, Lung, and Blood Institute (NHLBI) is listed as an others.

Does Three Lakes 12-20 have an API?

No public API is recorded for Three Lakes 12-20.

What industry is Three Lakes 12-20 in?

Three Lakes 12-20's product category is Medical Research Foundation. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 813211 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswirePaving the way for better diagnosis, treatment and care inThree Lakes Foundation expanded B4PF, an initiative for early diagnosis and therapeutic development of ILD/PF, partnering with Weill Cornell Medicine, Vanderbilt University Medical Center, and Radiomics. The project aims to use CT imaging to identify early signs of pulmonary fibrosis in relatives and individuals with incidental abnormalities. It targets over five million global PF patients and 50,000 U.S. IPF diagnoses annually.GlobeNewswireSteering committee of pulmonary and primary care experts aims to reduce time to diagnose complex lung diseasesCHEST and Three Lakes Foundation announced a steering committee of pulmonary and primary care experts to lead an initiative reducing diagnosis time for interstitial lung diseases. The committee will develop tools after surveys, aiming to address delays that can take years. Details will be presented at the 2022 American Thoracic Society conference.PR NewswireThree Lakes Foundation, Lung Foundation Australia and Centre of Research Excellence in PF join forces to create a global network for PF researchThree Lakes Foundation has partnered with Lung Foundation Australia and the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) to establish a global network for pulmonary fibrosis research. This collaboration aims to leverage shared expertise and resources to accelerate the diagnosis, treatment, and delivery of therapies for the disease.PR NewswireThree Lakes Foundation and MATTER to hold an Innovation Challenge for Pulmonary FibrosisThree Lakes Foundation and MATTER are launching an Innovation Challenge focused on developing new solutions for pulmonary fibrosis, a lung disease affecting approximately 200,000 people in the US. Over $100,000 is allocated for the best solutions aimed at improving diagnosis and care for patients with pulmonary fibrosis. The Challenge aims to spotlight the urgent need for advancements in PF solutions, especially in light of the COVID-19 pandemic's impact on respiratory health.